- About Us
- Guidelines
-
The Author ensures that the research has been conducted responsibly and ethically with adherence to all relevant regulations. read more..
- For Authors
- For Reviewer
- Manuscript Guidelines
- Membership
-
- Journals
- Reprints
- e-Books
- Videos
- Indexing
- Contact Us
COVID-19
- Submissions
Abstract
Surgical Medicine Open Access Journal
Bortezomib-Induced Blepharitis: A Case Report
-
Open or CloseAhmad Khalil¹, Pamela Sfeir¹, Antoine Abi Abboud², Kamal AlZahran1*, Elise
Slimᶾ and Evelyne Helou⁴
1 Department of Hematology-Oncology, Lebanon
2 Department of Gastro-Enterology, Lebanon
3 Department of Ophthalmology, Lebanon
4 Department of Hematology-Oncology, Lebanon
*Corresponding author: Kamal AlZahran, Department of Hematology-Oncology, Middle East Institute of Health (MEIH), Beirut, Lebanon.
Submission: January 16, 2020;Published: January 27, 2020
ISSN : 2578-0379Volume3 Issue3
Abstract
Introduction: Bortezomib is a proteasome inhibitor approved for the treatment of multiple myeloma and has known manageable toxicities. Blepharitis is an inflammatory condition of the eyelid that leads to formation of chalazia both causing visual field disturbance. Bortezomib induced blepharitis has not been well reported in the literature.
Case: we present a case of 76-year-old lady with multiple myeloma who developed bortezomibinduced blepharitis and chalazia. Patient was successfully treated after topical ocular therapy, systemic antibiotherapy and omission of bortezomib.
Keywords: Multiple myeloma; Blepharitis; Chalazia; Bortezomib
Editor In Chief
.jpg)
Signup for Newsletter
Quick Links
Editorial Board Registrations
Submit your Article
Best Paper of the Volume
Reprints
Refer a Friend
Advertise With UsOur Recent Edition
.jpg)
Top Editors
.jpg)
.bmp)
.jpg)
.png)
.jpg)
.png)
.png)
.png)
Financial Support
Sponsors
Latest e-Books
Latest Video
a Creative Commons Attribution 4.0 International License. Based on a work at www.crimsonpublishers.com.
Best viewed in 
| Above IE 9.0 version